Zoetis’ Cytopoint is first monoclonal antibody (mAb) therapy approved in the European Union for veterinary use

European Commission has granted marketing authorization for Zoetis’ Cytopoint (lokivetmab), the first monoclonal antibody (mAb) therapy approved in the European Union for veterinary use.

Cytopoint is indicated to treat the clinical signs, including itching and inflammation, associated with atopic dermatitis in dogs of any age weighing 3 kilograms or more. Cytopoint targets and neutralizes canine interleukin-31 (cIL-31), a key protein involved in triggering itch in dogs. Administered by injection once monthly, Cytopoint provides fast, long-lasting relief of itching – the hallmark sign of the allergic skin condition atopic dermatitis in dogs – and the inflammation and lesions it causes. Cytopoint helps improve the long-term health and quality of life for dogs suffering from atopic dermatitis and eases the related frustration and concern of their owners.